基于痘苗病毒的抗传染病和肿瘤载体。
Vaccinia virus-based vector against infectious diseases and tumors.
作者信息
Zhang Ziling, Dong Lanlan, Zhao Chen, Zheng Peiyong, Zhang Xiaoyan, Xu Jianqing
机构信息
Shanghai Public Health ClinicalCenter& Institutes of Biomedical Science, Shanghai Medical College, Fudan University, Shanghai, China.
Institute of Digestive Diseases, LongHua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
出版信息
Hum Vaccin Immunother. 2021 Jun 3;17(6):1578-1585. doi: 10.1080/21645515.2020.1840887. Epub 2021 Feb 19.
Abstract
Vaccinia virus was used to prevent smallpox. After the World Health Organization declared smallpox extinct, vaccinia virus has been explored for the development of vaccines against a variety of infectious diseases. It also finds a new place in oncolytic therapy. Here we provide a brief review of the history, current status, and future prospect of vaccinia virus-based vaccine and oncolytic virus. New advancements, including a single vaccine targeting multiple viruses, strategies of arming vaccinia viruses to enhance anti-tumor activity, the promise and challenge of combining vaccinia-based virotherapy with immunotherapy, are discussed as special focus.
摘要
痘苗病毒曾被用于预防天花。在世界卫生组织宣布天花灭绝后，人们对痘苗病毒进行了探索，以开发针对多种传染病的疫苗。它在溶瘤治疗中也找到了新的应用领域。在此，我们简要回顾基于痘苗病毒的疫苗和溶瘤病毒的历史、现状及未来前景。作为特别关注点，还讨论了包括靶向多种病毒的单一疫苗、增强痘苗病毒抗肿瘤活性的武装策略、基于痘苗病毒的病毒疗法与免疫疗法联合应用的前景与挑战等新进展。
相似文献
1
Vaccinia virus-based vector against infectious diseases and tumors.基于痘苗病毒的抗传染病和肿瘤载体。
Hum Vaccin Immunother. 2021 Jun 3;17(6):1578-1585. doi: 10.1080/21645515.2020.1840887. Epub 2021 Feb 19.
2
Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.Tian Tan 株 GM-CSF 武装痘苗病毒的溶瘤和免疫肿瘤治疗。
Cancer Lett. 2016 Mar 28;372(2):251-7. doi: 10.1016/j.canlet.2016.01.025. Epub 2016 Jan 21.
3
Progress in gene therapy using oncolytic vaccinia virus as vectors.溶瘤痘苗病毒作为载体的基因治疗进展。
J Cancer Res Clin Oncol. 2018 Dec;144(12):2433-2440. doi: 10.1007/s00432-018-2762-x. Epub 2018 Oct 6.
4
Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.缺失胸苷激酶的痘苗病毒株Guang9的溶瘤效力
Oncotarget. 2017 Jun 20;8(25):40533-40543. doi: 10.18632/oncotarget.17125.
5
Recent progress in combination therapy of oncolytic vaccinia virus.溶瘤痘苗病毒联合治疗的最新进展。
Front Immunol. 2024 Mar 13;15:1272351. doi: 10.3389/fimmu.2024.1272351. eCollection 2024.
6
Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.溶瘤痘苗病毒在癌症免疫治疗中的临床前和临床试验：全面综述。
Cancer Biol Med. 2023 Aug 23;20(9):646-61. doi: 10.20892/j.issn.2095-3941.2023.0202.
7
IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.IL-21 武装增强了单纯治疗和联合治疗中溶瘤痘苗病毒的抗肿瘤活性。
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001647.
8
Oncolytic vaccinia virus and cancer immunotherapy.溶瘤痘苗病毒与癌症免疫疗法。
Front Immunol. 2024 Jan 12;14:1324744. doi: 10.3389/fimmu.2023.1324744. eCollection 2023.
9
Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).一种新型溶瘤痘苗病毒的抗肿瘤疗效增强，该病毒编码针对 T 细胞免疫球蛋白和 ITIM 结构域（TIGIT）的完全单克隆抗体。
EBioMedicine. 2021 Feb;64:103240. doi: 10.1016/j.ebiom.2021.103240. Epub 2021 Feb 10.
10
The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies.痘苗病毒在结直肠癌治疗中的应用：临床前和临床研究综述。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2143698. doi: 10.1080/21645515.2022.2143698. Epub 2022 Nov 11.
引用本文的文献
1
Codon Usage Evolution in Viruses: Implications for Survival and Pathogenicity.病毒中的密码子使用进化：对生存和致病性的影响
J Mol Evol. 2025 Sep 4. doi: 10.1007/s00239-025-10263-7.
2
Efficacy and immunogenicity of rKVAC85B in a BCG prime-boost regimen against H37Rv and HN878 Mycobacterium tuberculosis strains.rKVAC85B在卡介苗初免-加强免疫方案中对H37Rv和HN878结核分枝杆菌菌株的疗效和免疫原性。
PLoS One. 2025 May 14;20(5):e0322147. doi: 10.1371/journal.pone.0322147. eCollection 2025.
3
Cancer vaccines: an update on recent achievements and prospects for cancer therapy.癌症疫苗：癌症治疗近期成果与前景的最新进展
Clin Exp Med. 2024 Dec 25;25(1):24. doi: 10.1007/s10238-024-01541-7.
4
A multi-antigen vaccinia vaccine broadly protected mice against SARS-CoV-2 and influenza A virus while also targeting SARS-CoV-1 and MERS-CoV.一种多抗原痘苗病毒疫苗可广泛保护小鼠免受严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和甲型流感病毒感染，同时还能靶向严重急性呼吸综合征冠状病毒1（SARS-CoV-1）和中东呼吸综合征冠状病毒（MERS-CoV）。
Front Immunol. 2024 Nov 28;15:1473428. doi: 10.3389/fimmu.2024.1473428. eCollection 2024.
5
Microchip construction for migration assays: investigating the impact of physical confinement on cell morphology and motility during vaccinia virus infection.微芯片构建用于迁移分析：研究物理限制对痘病毒感染过程中细胞形态和迁移能力的影响。
Anal Bioanal Chem. 2024 Nov;416(26):5605-5618. doi: 10.1007/s00216-024-05485-5. Epub 2024 Aug 19.
6
Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.牛痘病毒：支持免疫逃逸和成功的长期保护免疫的机制。
Viruses. 2024 May 29;16(6):870. doi: 10.3390/v16060870.
7
Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development.严重发热伴血小板减少综合征病毒（SFTSV）疫苗研发的最新进展。
Viruses. 2024 Jan 16;16(1):128. doi: 10.3390/v16010128.
8
Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.DNA 病毒的肿瘤趋向性用于溶瘤病毒治疗。
Viruses. 2023 Nov 16;15(11):2262. doi: 10.3390/v15112262.
9
Positioning SUMO as an immunological facilitator of oncolytic viruses for high-grade glioma.将SUMO定位为溶瘤病毒治疗高级别胶质瘤的免疫促进剂。
Front Cell Dev Biol. 2023 Oct 4;11:1271575. doi: 10.3389/fcell.2023.1271575. eCollection 2023.
10
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection.一种靶向T细胞的多抗原疫苗可产生针对新冠病毒感染的强大细胞免疫和体液免疫。
Mol Ther Methods Clin Dev. 2023 Sep 16;31:101110. doi: 10.1016/j.omtm.2023.101110. eCollection 2023 Dec 14.
本文引用的文献
1
An Oncolytic Vaccinia Virus Armed with GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy.一种携带GM-CSF和IL-24双基因的溶瘤痘苗病毒用于癌症靶向治疗。
Onco Targets Ther. 2020 Apr 28;13:3535-3544. doi: 10.2147/OTT.S249816. eCollection 2020.
2
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.一种用于中东呼吸综合征的改良安卡拉痘苗病毒载体候选疫苗的安全性和免疫原性：一项开放性、1 期临床试验。
Lancet Infect Dis. 2020 Jul;20(7):827-838. doi: 10.1016/S1473-3099(20)30248-6. Epub 2020 Apr 21.
3
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.急性治疗的 HIV 患者中 Ad26 和 MVA 疫苗的安全性和免疫原性，以及对中断抗逆转录病毒治疗后病毒反弹的影响。
Nat Med. 2020 Apr;26(4):498-501. doi: 10.1038/s41591-020-0774-y. Epub 2020 Mar 23.
4
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.南非泰国 RV144 HIV 疫苗方案的免疫相关性。
Sci Transl Med. 2019 Sep 18;11(510). doi: 10.1126/scitranslmed.aax1880.
5
'Mosaic' HIV vaccine to be tested in thousands of people across the world.“马赛克”艾滋病疫苗将在全球数千人身上进行测试。
Nature. 2019 Aug;572(7768):165-166. doi: 10.1038/d41586-019-02319-8.
6
Influenza Vaccine With Consensus Internal Antigens as Immunogens Provides Cross-Group Protection Against Influenza A Viruses.以共有内部抗原作为免疫原的流感疫苗可提供针对甲型流感病毒的跨组保护。
Front Microbiol. 2019 Jul 16;10:1630. doi: 10.3389/fmicb.2019.01630. eCollection 2019.
7
Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function.糖蛋白B5R的部分缺失增强痘苗病毒的中和逃逸能力，同时保留溶瘤功能。
Mol Ther Oncolytics. 2019 May 21;14:159-171. doi: 10.1016/j.omto.2019.05.003. eCollection 2019 Sep 27.
8
Combinatory effects of vaccinia virus VG9 and the STAT3 inhibitor Stattic on cancer therapy.痘苗病毒VG9与STAT3抑制剂Stattic对癌症治疗的联合作用。
Arch Virol. 2019 Jul;164(7):1805-1814. doi: 10.1007/s00705-019-04257-2. Epub 2019 Apr 24.
9
By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.通过结合 CD80 和 CD86，牛痘病毒 M2 蛋白阻断了它们与 CD28 和 CTLA4 的相互作用，并增强了 CD80 与 PD-L1 的结合。
J Virol. 2019 May 15;93(11). doi: 10.1128/JVI.00207-19. Print 2019 Jun 1.
10
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance.人表皮生长因子受体2阳性乳腺癌：新的治疗前沿与克服耐药性
Ther Adv Med Oncol. 2019 Mar 19;11:1758835919833519. doi: 10.1177/1758835919833519. eCollection 2019.
Zotero 插件